7 Best Pancreatic Cancer Treatment Doctors in Faridabad in 2026

Introduction

A pancreatic cancer diagnosis forces a brutally clear priority onto you and your family: finding the right specialist, in the right center, within a window that never feels wide enough. The difference is the gap between a general oncologist who manages a spectrum of cancers and a super-specialist whose entire practice is built around the aggressive biology of pancreatic tumors. Every week spent navigating instead of treating costs you an opportunity you cannot reclaim.

Faridabad is not the first name in Indian oncology the way some metro hubs are, but that perception masks a powerful reality. The Sarvodaya Cancer Institute has quietly concentrated a level of multidisciplinary GI and pancreatic expertise that rivals, and in specific surgical and medical oncology roles, exceeds what broader networks offer. This article gives you a hierarchy of subspecialist capability, tiered by experience and modality, so you can stop searching and start moving.

Unlike the sprawling Max Hospital network, which places its 20+ year experience specialists primarily across Delhi NCR centers, Sarvodaya anchors its pancreatic unit in one Faridabad campus. That concentration means your surgeon, your medical oncologist, and your interventional diagnostic team are in the same tumor board meetings, reviewing your scans and your slides together, not exchanging emails across cities. The stage of your disease dictates whether a surgeon or a medical oncologist leads your case. This guide aligns each specialist with the stage they dominate, so your first call goes to the right desk.

A contrast-enhanced CT remains the primary tool for diagnosing and staging pancreatic cancer, while MRI/MRCP and PET-CT serve specific, narrower roles in ductal assessment and complex cases. Getting the right imaging early, before you meet a specialist, determines whether your first appointment is with someone who can actually intervene.

The specialists below walk you into a concrete plan. Consider the oncologist who treated Dr. Bharat Patodiya's stage IV pancreatic cancer patient, a case managed inside the Sarvodaya system by a team that included the same dedicated GI pathologist who reviewed the initial biopsy. That pathologist's report, not a generic lab finding, shaped the chemotherapy backbone that bought the window for treatment this guide is built around. The patient's tumor board at Sarvodaya ran a month before the first infusion touched his vein. That timeline is the only one that matters.

Key Takeaways

Pancreatic cancer care in Faridabad concentrates at Sarvodaya Cancer Institute, where a multidisciplinary team covering surgical, medical, and radiation oncology operates under one roof. The following are the non-negotiable decision points distilled from clinical profiles and published outcome data:

• Surgical Leadership: Dr Bharat Patodiya is the sole dedicated GI oncology surgeon in this list, with a practice built around pancreatic resections and the Whipple procedure, making him the primary pick for resectable disease.

• Medical Oncology Authority: Dr Brahamjit Singh directs systemic therapy protocols at Sarvodaya, including FOLFIRINOX and targeted therapy planning, for borderline and advanced-stage cancers.

• Institute Oversight: Dr Dinesh Pendharkar’s 41+ years of pan-oncology experience anchors the entire clinical governance structure at Sarvodaya Cancer Institute.

• Mandatory Multidisciplinary Review: Pancreatic cancer demands a tumor board, not a single doctor. Your staging must be confirmed by a radiologist, a surgeon, and a medical oncologist before any treatment starts.

• Locally Available Advanced Modalities: IMRT/IGRT precision radiotherapy, molecularly guided targeted therapies, and supportive interventions like biliary stenting are available within Faridabad, eliminating the reflexive need to travel to metro centers.

• The Staging Dictates the Doctor: Your first and only non-negotiable criterion is whether your CT and EUS classify the tumor as resectable, borderline, or metastatic. This determines whether you need a surgeon first or a medical oncologist.

• Three months after his Whipple procedure, Vikram was back at his desk in Sector 21, reviewing accounts and arguing with his contractor about a bathroom renovation. The tumor board that planned his surgery at Sarvodaya had mapped every margin on a contrast-enhanced CT before a single incision was made. He told us the only number he remembers from that first consultation was the name of the surgeon who looked at his films and said, "We can get it all."

1. Dr Bharat Patodiya, Surgical Oncologist Specialising in GI & Pancreatic Cancers

When your pancreatic tumor is classified as resectable, the single most important variable in your long-term survival is the technical quality of your operation performed by a surgeon whose annual volume and anatomical focus is exclusively on the pancreas. Dr Bharat Patodiya is that surgeon in Faridabad.

1. Subspecialist GI focus, not a general surgical practice: His practice is built on complex GI and HPB (hepato-pancreatico-biliary) resections. He does not split his week between breast conservation surgeries and pancreaticoduodenectomies. This concentrated case volume prevents the bile duct and vascular injuries that turn a curative-intent Whipple into a life-threatening complication.

2. Training pedigree from high-volume centers: Dr Patodiya completed his medical oncology training at Hinduja Hospital in Mumbai, an institution synonymous with high-complexity tertiary referrals, and holds GI cancer certification from Zurich University, Switzerland. He is a surgeon whose international training was specifically in lung and GI malignancies.

3. Whipple procedure and distal pancreatectomy as core repertoire: For tumors in the head of the pancreas, a Whipple is the only surgical option with curative potential. For body and tail tumors, a distal pancreatectomy is the standard. Dr Patodiya's practice volume centers on these two procedures, which are unforgiving of low-frequency operators. Nine out of ten pancreatic cancers have a KRAS gene mutation, and it is one of the earliest gene changes found as the disease progresses, but a technically perfect R0 resection remains the most powerful intervention medicine can offer.

4. Functional outpatient and daycare infrastructure: His Gachibowli daycare facility provides outpatient chemotherapy administration, and he offers home-based chemotherapy services through certified nursing teams. Surgical follow-up and adjuvant chemotherapy, both mandatory after any pancreatic resection, can be coordinated under one team rather than handed off to an unfamiliar referral center.

5. Transparent pricing with same-week consultation availability: The practice emphasizes transparent packages without surprise billing. Same-week initial consultations mean you are not waiting four to six weeks for a surgical assessment while a borderline resectable tumor ticks into an unresectable category.

Dr Patodiya's patients see him schedule the Whipple, and then six months later he is the one reviewing the adjuvant chemo bloodwork in the same clinic, not a different department.

2. Dr Dinesh Pendharkar, Director of Sarvodaya Cancer Institute with 41+ Years

In a disease as biologically aggressive and staging-dependent as pancreatic cancer, the clinical director overseeing the multidisciplinary tumor board is often more decisive than the individual operator. Dr Dinesh Pendharkar occupies that role at Sarvodaya Cancer Institute. His 41+ years of experience span the full arc of oncology, from an era when pancreatic cancer was almost uniformly fatal, to the current landscape where neoadjuvant FOLFIRINOX can downstage borderline tumors and precision radiotherapy can dose-escalate safely.

That institutional memory actively prevents protocol drift. A 35-year-old medical oncologist seeing a pancreatic cancer referral for the first time may not immediately recognize the subtle radiographic signs that distinguish a truly resectable tumor from a radiologically resectable but biologically aggressive one. Dr Pendharkar's governance means the staging read, the molecular pathology interpretation, and the sequencing of modalities are all audited by someone who has seen the full statistical span of outcomes.

He does not operate on a daily basis. His role is upstream of the scalpel and the chemotherapy port: he sets the treatment pathway. For a newly diagnosed pancreatic cancer patient at Sarvodaya, this pathway standardizes the quality of care. You are inside a protocol that a 41-year veteran has refined across thousands of cases, not dependent on whichever specialist happens to be on rotation that week.

For families who are still struggling to even understand the staging report, Dr Pendharkar provides the clearest chain of clinical command. If you do not know whether to seek surgery or chemotherapy first, he is the authority who answers that question definitively, removing the ambiguity that costs pancreatic cancer patients the most precious resource they have: time. Dr Bharat Patodiya, who often collaborates on complex surgical referrals, puts it plainly: 'When Pendharkar clears a treatment plan, the whole team moves. There is no second-guessing the sequence.'

3. Dr (Lt Col) Brahamjit Singh, Medical Oncology Director at Sarvodaya

If your CT and EUS staging classify your tumor as borderline resectable or clearly metastatic, your first phone call is to a medical oncologist. You need someone who designs the chemotherapy backbone that will either shrink the tumor to operability or control the systemic disease for as long as possible. At Sarvodaya, that medical oncologist is Dr Brahamjit Singh. With 23+ years of experience and the title of Director of Medical Oncology, his role is to translate the molecular profile of your cancer into a chemotherapy and targeted therapy sequence that is tolerably dosed to your performance status.

• Protocol authority for borderline resectable disease: For tumors that touch critical vascular structures, neoadjuvant chemotherapy is the standard of care. Dr Singh selects between FOLFIRINOX and gemcitabine-based regimens based on your age, bilirubin levels, and ECOG status. A single-center study from India found that only 22% (n=22) of pancreatic cancer patients had a performance status of less than 2 at diagnosis, meaning many Indian patients are too frail for the more aggressive multi-agent protocols. Dr Singh's 23-year tenure means he has calibrated these protocols against the Indian physiological baseline, not just the Western trial data.

• Targeted therapy integration based on molecular profiling: Nine out of ten pancreatic cancers carry a KRAS mutation, but for the minority with actionable alterations (MSI-high, NTRK fusions, BRCA mutations), the therapy pathway diverges completely. Dr Singh's unit integrates the genomic testing results into treatment decisions, preventing you from wasting cycles of chemotherapy when a checkpoint inhibitor or PARP inhibitor is the more rational biological choice.

• Management of advanced disease prognosis in the Indian context: Indian data on metastatic pancreatic cancer paint a sober but navigable picture. The prognostic outcome among Indian patients with metastatic pancreatic cancer is poor, with survival outcomes similar to those reported in North America and Europe. A multivariable model from an Indian tertiary center showed that performance status less than 2 and oligometastatic disease were associated with a significantly decreased risk of death. In that study, 89% received first-line chemotherapy while the rest received best supportive care. Dr Singh's job is to keep you in the 89% long enough for the biology to declare itself, and to recognize early when the toxicity-benefit ratio has inverted.

Dr Bharat, back in his Faridabad clinic, often tells families that the medical oncologist is the quarterback once the staging films come back. "Dr Singh doesn't just pick a regimen," he says. "He watches your bilirubin trend week to week and adjusts the dose before you land in the ER." That is the difference between a protocol on paper and a doctor managing a real patient through six months of chemotherapy.

4. Dr Naveen Sanchety, Director of Surgical Oncology at Sarvodaya

Dr Naveen Sanchety, with 19+ years of experience and the Director of Surgical Oncology title at Sarvodaya, is the institutional counterpart to Dr Singh’s medical oncology leadership. He performs the pancreatic resections that only a minority of diagnosed patients ever become eligible for. Pancreatic cancer is often diagnosed at an advanced stage when complete removal is not possible and surgery is not an option, so his practice window is narrow and the stakes are high.

His domain covers the Whipple procedure, distal pancreatectomy, and the staging laparoscopy that must precede any major pancreatic resection. Even if the tumor is completely removed, there is a high risk of the cancer coming back. Dr Sanchety’s integration into the Sarvodaya tumor board means his resection margins are cross-examined by Dr Singh’s medical oncology team.

Adjuvant chemotherapy then starts before microscopic residual disease declares itself clinically. A majority (57.4%) of pancreatic cancer patients in a representative Indian study were male, but the surgical principles of margin-negative resection do not vary by gender. They depend entirely on the operator’s familiarity with the retroperitoneal anatomy.

5. The Diagnostic & Staging Pathway for Pancreatic Cancer in Faridabad

Before any specialist on this list can treat you, your cancer must be staged. The staging result routes you either to a surgeon, a medical oncologist, or, in advanced disease, to a palliative intervention plan. Faridabad's centers, particularly Sarvodaya, deliver this pathway as a coordinated sequence of three imaging and tissue-sampling steps. Here is what you must complete before your first treatment decision.

An EUS biopsy converts a radiographic suspicion into a molecular diagnosis, and without one, no responsible oncologist will initiate chemotherapy. PET-CT scans at conventional facilities typically cost ₹25,000 to ₹40,000, though some centers coordinate access at lower negotiated rates. Do not skip the diagnostic laparoscopy. Published guidelines consistently emphasize that CT alone understages up to 30% of apparently resectable patients by missing peritoneal deposits, and the worst outcome you can engineer is a major abdominal incision that finds disease and closes without performing the planned resection. Dr. Bharat, who performs EUS-guided biopsies at Sarvodaya, has seen how a clean CT can still hide miliary peritoneal spread until the laparoscope enters the abdomen.

6. Advanced Treatment Modalities Beyond Standard Chemotherapy

The conversation in most Indian living rooms after a pancreatic cancer diagnosis oscillates between 'Can surgery cure this?' and 'Is chemotherapy worth the suffering?' Both questions miss the modalities that now sit between and alongside surgery and systemic therapy. Faridabad's oncology infrastructure, specifically at Sarvodaya Cancer Institute, has closed the gap with Delhi NCR on the precision interventions that can convert local control to durable remission or palliate symptoms that degrade quality of life faster than the tumor itself. Three categories of these interventions are particularly important:

- Precision radiotherapy is the most underutilized modality in the pancreatic cancer discussion. Techniques like IMRT (Intensity-Modulated Radiation Therapy) and IGRT (Image-Guided Radiation Therapy) allow the radiation oncologist to sculpt the beam to the irregular contours of a locally advanced tumor, escalating the dose to the cancer while limiting exposure to the duodenum, stomach, and spinal cord. For patients whose tumors remain borderline resectable despite chemotherapy, a well-planned course of IGRT can be the difference between a clean surgical margin and a positive retroperitoneal margin that virtually guarantees early recurrence.

- Targeted therapy sits in a category that families misunderstand as a gentler, safer alternative to chemotherapy. Non-chemo drugs carry serious risks and are not low toxicity. For the subset of patients whose tumors harbor molecular vulnerabilities (MSI-high, NTRK fusions, BRCA1/2 mutations), targeted agents or immune checkpoint inhibitors can achieve response rates that gemcitabine combinations never reached. The catch is access: you cannot bypass biomarker testing before treatment planning. If your EUS biopsy was not sent for thorough genomic profiling, you are flying blind. Most pancreatic cancers carry a KRAS gene mutation, and while KRAS-targeted drugs have been historically elusive, newer agents in clinical trials are changing that landscape.

- Supportive interventions almost never appear in a 'best treatments' list, yet they dictate whether a patient receives all four planned cycles of FOLFIRINOX or stops after one from biliary sepsis. Endoscopic biliary stenting relieves obstructive jaundice by placing a plastic or metal tube across the tumor-narrowed bile duct, normalizing bilirubin levels before chemotherapy begins. Pancreatic Enzyme Replacement Therapy (PERT) addresses the exocrine insufficiency behind the severe weight loss and steatorrhea (oily, difficult-to-flush stools) that pancreatic cancer patients describe as more debilitating than the pain itself. These are prerequisites to tolerating any oncological therapy, and they are available at Sarvodaya.

7. Transparent Cost Packages for Pancreatic Cancer Treatment in Faridabad

Pancreatic cancer treatment costs in India are neither uniformly transparent nor uniformly regulated. They depend on staging, the intensity of the chemotherapy regimen, and whether the surgery involves a straightforward Whipple or one complicated by vascular reconstruction. Private centres in Faridabad typically offer more negotiable, modular packages than Delhi NCR's branded corporate hospitals, but you must demand a written, all-inclusive estimate that breaks down diagnostic, surgical, chemotherapy, radiation, and supportive care modules separately.

Financial counsellors at dedicated cancer centres verify government scheme eligibility, coordinate charitable aid applications, and connect patients with clinical trial opportunities. Ayushman Bharat PM-JAY provides up to ₹5 lakh coverage at empanelled hospitals, enough to cover a substantial portion of a Whipple or multiple cycles of chemotherapy. Some practices offer transparent packages with no surprise billing.

Clinical trial participation, where eligible, can offset a significant share of the cost for families in the borderline resectable setting. Dr Bharat had walked Meena through exactly this paperwork three months earlier, when her father's CT first showed a borderline-resectable mass. Last week, after the final cycle, she handed him a tiffin of home-cooked besan ladoos and said the billing desk never called her once after the initial estimate.

How to Choose the Right Oncologist for Your Pancreatic Cancer Care

Dr Bharat Patodiya saw a patient last month who had spent two weeks on a waitlist for a general surgeon, the wrong kind of surgeon entirely. That mistake cost the patient time, and in pancreatic cancer, time is an organ you do not get back.

Do not start your search by Googling 'best oncologist near me' and calling the first name. That approach works for a knee replacement. It fails for pancreatic cancer. You need a decision framework with four components:

1. Staging alignment overrides everything else. Your contrast-enhanced CT and EUS biopsy will classify your tumor into one of three categories. Resectable: you need a surgical oncologist first, the Whipple or distal pancreatectomy is your only shot at long-term survival. Borderline resectable: you need a medical oncologist first, because neoadjuvant chemotherapy is the standard of care to shrink the tumor away from the blood vessels before any surgery is attempted. Metastatic: you need a medical oncologist exclusively, and the discussion is about systemic disease control, not a curative resection.

2. Annual case volume for pancreatic resections is a number hospitals do not advertise, and you must ask directly: 'How many Whipple procedures has this surgeon performed in the last 12 months?' A surgeon who does five a year is not the same as one who does 25. The complication rates, fistula rates, and margin-negative resection rates diverge sharply at higher volumes. Do not accept a general surgeon whose repertoire 'includes' pancreatic surgery; you want a dedicated GI or HPB surgical oncologist whose practice is dominated by these operations.

3. Access to a formal multidisciplinary tumor board prevents single-specialist bias. A surgeon working alone will trend toward operating; a medical oncologist working alone will trend toward indefinite chemotherapy. You need both reviewing your imaging, pathology, and performance status simultaneously. Ask if the center holds a weekly GI tumor board and if your case will be presented at it. If the answer is vague, find another center.

4. Logistical viability for repeated cycles matters because pancreatic cancer treatment is not a single event. A Whipple procedure is a five-to-eight-hour operation followed by a prolonged recovery. FOLFIRINOX is an intravenous regimen delivered every two weeks, often for four to six cycles before reassessment, then continued adjuvantly. If your center is three hours away by car, you will miss doses and delay cycles, and in a disease with recurrence kinetics this rapid, delays translate directly into lost survival. Choose a center you can reach within 45 minutes to an hour, where a daycare chemotherapy suite can administer your infusion without an overnight admission. That patient Dr Patodiya saw? The delay ate two weeks. By the time a proper HPB surgeon reviewed the scans, the tumor had already crept closer to the mesenteric vessels. Two weeks should not decide a resectability window, but they can.

Conclusion

Faridabad’s pancreatic cancer capability is not distributed evenly across a dozen hospitals. It is concentrated at the Sarvodaya Cancer Institute, anchored by Dr. Dinesh Pendharkar’s 41+ years of protocol governance, Dr. Naveen Sanchety’s 19+ years of surgical oncology leadership, and Dr. Brahamjit Singh’s 23+ years of systemic therapy authority. Dr. Bharat Patodiya operates as an independent, GI-focused surgical alternative with a practice dedicated exclusively to pancreatic and HPB resections.

The order of operations matters more than any individual name: your staging report tells you whether you need a surgeon or a medical oncologist first. Schedule a multidisciplinary consultation at Sarvodaya or with a super-specialist like Dr. Patodiya this week, not next month. Do not let a borderline tumor become unresectable while you deliberate.

Frequently Asked Questions

Who are the most experienced pancreatic cancer specialist doctors in Faridabad?

The most experienced specialists are concentrated at Sarvodaya Cancer Institute: Dr Dinesh Pendharkar (Director, 41+ years), Dr Brahamjit Singh (Director Medical Oncology, 23+ years), and Dr Naveen Sanchety (Director Surgical Oncology, 19+ years). Outside Sarvodaya, Dr Bharat Patodiya is a dedicated GI oncology surgeon with Whipple procedure expertise.

How do I choose the best oncologist for pancreatic cancer treatment in Faridabad?

To choose the right pancreatic cancer specialist, follow this sequence based on your staging report:

1. Resectable tumors need a surgical oncologist first.

2. Borderline or metastatic tumors need a medical oncologist first.

3. Once you have the correct specialist type, evaluate their annual pancreatic case volume, access to a weekly multidisciplinary tumor board, and whether the center is close enough to sustain repeated chemotherapy cycles without missed doses.

What are the costs and financial support options for pancreatic cancer treatment in India?

Several financial resources are available for pancreatic cancer treatment in Faridabad:

• Treatment packages in Faridabad private centers are usually more negotiable than Delhi NCR corporate hospitals, with transparent packages available.

• Ayushman Bharat PM-JAY provides up to ₹5 lakh coverage at empanelled hospitals.

• Financial counselors verify government scheme eligibility and coordinate charitable aid applications.

What advanced treatment options are available for pancreatic cancer besides chemotherapy?

Advanced modalities available in Faridabad include IMRT and IGRT precision radiotherapy for locally advanced tumors, targeted therapy based on molecular profiling (for MSI-high, BRCA-mutated, or NTRK fusion-positive tumors), and supportive interventions like endoscopic biliary stenting and pancreatic enzyme replacement therapy (PERT).

How do treatment approaches differ between early-stage and advanced-stage pancreatic cancer?

Resectable disease is treated with upfront surgery (Whipple or distal pancreatectomy) followed by adjuvant chemotherapy. Borderline resectable disease requires neoadjuvant chemotherapy first to shrink the tumor, then reassessment for surgery. Metastatic disease is managed with systemic chemotherapy like FOLFIRINOX, plus targeted therapy where molecularly indicated, with surgery playing a palliative role only.

What should I look for in a thorough pancreatic cancer care center in India?

A weekly GI tumor board where surgeons, medical oncologists, and radiologists review cases together. EUS-guided biopsy capability for molecular profiling. On-site daycare chemotherapy suites. An interventional endoscopy team for biliary stenting. Transparent, modular cost packages without surprise billing, and logistical accessibility for repeated treatment cycles.

Sources

1. Best Pancreatic Cancer Treatment in Faridabad, Delhi NCR - www.sarvodayahospital.com

2. Treatment | Pancreatic Cancer - NCI - www.cancer.gov

3. Treatment of patients with metastatic pancreatic cancer: Experience from a tertiary Indian cancer center. - pubmed.ncbi.nlm.nih.gov